Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shengmai San for Prevention of Cardiotoxicity in Breast Cancer
NCT06214195Phase 3Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of shengmai san in Cardiotoxicity (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Incidence of cardiotoxicity at 1.5 years. Started Jan 2024; status: recruiting.
02
Drugs
shengmai san
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT06214195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214195.